Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab

Marta Castiglia, Angela Listi', Antonio Russo, Francesco Passiglia, Alessandro Perez, Chiara Ancona, Emmanuela Musso, Sergio Rizzo

Risultato della ricerca: Otherpeer review

Abstract

Nivolumab is a programmed death-1 (PD-1)inhibitor recently approved for the treatment of NSCLC patients who failed prior chemotherapy. Searching for predictive biomarkers of immunotherapy efficacy is an area of intensive investigation for translational research. Monitoring circulating tumor DNA (ctDNA) during nivolumab treatment could help clinicians to predict the immunotherapy efficacy and ultimately improve the management of patients
Lingua originaleEnglish
Numero di pagine0
Stato di pubblicazionePublished - 2017

Fingerprint

Entra nei temi di ricerca di 'Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with Nivolumab'. Insieme formano una fingerprint unica.

Cita questo